Virginia Commonwealth University
Tacrolimus is not Neuroprotective Against Bilirubin Induced Auditory Impairment
Abstract
dc:description.abstractIn newborns, unconjugated bilirubin (UCB) is not readily excreted, and when bilirubin levels exceed the serum albumin binding capacity, pathological levels of UCB exist. Hyperbilirubinemia may lead to auditory damage and ultimately cause a hearing disorder called auditory neuropathy/dys-synchrony, characterized by absent or abnormal brainstem auditory evoked potentials (BAEPs) with evidence of normal inner ear function assessed by either otoacoustic emissions or cochlear microphonic responses. Phototherapy and double volume exchange transfusion are used as treatment methods for neonatal hyperbilirubinemia. Spontaneously jaundiced Gunn rat pups given sulfadimethoxine to displace bilirubin from serum albumin develop bilirubin encephalopathy and have abnormal BAEPs comparable to human neonates. BAEPs are a noninvasive electrophysiological measure of neural function of the auditory system. High levels of calcineurin activity are believed to be involved in the mechanism of this bilirubin induced auditory neuropathy. FK506, a calcineurin inhibitor, was administered 3 hours prior to sulfa in concentrations of 0.1mg/kg, 1.0mg/kg, and 10.0mg/kg body weight. Due to the observation that all animals had abnormal BAEPs after treatment with FK506 and sulfa, it can be concluded that none of the treatment doses protected against bilirubin induced auditory impairment.
Degree
thesis:*- Name thesis:degree_name
- Master of Science
- Level thesis:degree_level
- Thesis
- Discipline thesis:degree_discipline
- Physiology
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Walker, Lori
- Contributors dc:contributor
-
- Steven Shapiro
- Ann Rice
- George Ford
Subjects
dc:subject × 7Rights
dc:rights- Statement dc:rights
-
- © The Author
Identifiers
dc:identifier.*- Identifier
- https://scholarscompass.vcu.edu/etd/1736